secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001628280-24-000776
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q4 preliminary revenue $32.7M, down 26% YoY; cell processing up 11% sequentially
--------------------------------------------------------------------------------

- Q4 2023 total preliminary unaudited revenue $32.7M, down 26% vs Q4 2022 ($44.3M).
- Cell processing platform revenue $14.8M, down 27% YoY but up 11% sequentially from Q3 2023.
- Full-year 2023 revenue $143.3M, down 11% from $161.8M in 2022.
- Divestiture of freezer business progressing; expected to close in Q1 2024.
- CEO cites 14 approved CGT therapies using BioLife products; 10 more potential by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/blfs-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-000776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer